Abstract
The demand for biopharmaceuticals is increasing, but little progress is being
made to reduce production costs or increase manufacturing capacity. There are
insufficient facilities to cope with the demand for products and new leads in
drug discovery. The use of recombinant plants as factories to express
recombinant proteins has the potential to alleviate this bottleneck. The
production platforms and technologies that enable this are now in place and the
onus is squarely on product development to commercially introduce therapeutics,
and several companies have attracted venture capital sponsorship, and they are
likely to be in a position to achieve this within the next two years.
This Frost & Sullivan strategic analysis service provides an overview of
and outlook for the world plant molecular farming (biofarming) market. The study
provides information on the world industry dynamics with a particular focus on
North America and Europe as major centers of activity in this sector. It also
offers strategic recommendations that enable companies to align their
positioning strategies to benefit from the changing markets and obtain maximum
return on investment.
Transgenic Plants Have the Potential to Improve Biopharmaceutical
Production Efficiency
Biopharmaceutical manufacturers concerns about production capacity can be
eased by investing in new manufacturing technologies and methods such as using
transgenic plants as factories to produce biopharmaceuticals. "The cost of
production can be significantly reduced by producing larger volumes, and
eliminating the need for capital investment in fermentation systems," says
the analyst of this research.
Using microscopic plants such as lemna or moss in bioreactors have the
potential to eliminate containment problems and improve turnover times by
simplifying recombination procedures.
Drug Discovery Market Governed by Regulatory Affairs and Public Perception
Currently, there are no biopharmaceutical products manufactured using plant
molecular farming in the market, with the first products anticipated to reach
the market around 2005-06. However, the U.S. market could be worth $2.20 billion
in 2011, as this emerging sector rapidly gathers pace as public perception and
the regulatory climate improve. Growth is likely to occur fastest between 2008
and 2010 as more products enter the market and receive regulatory approval.
"The gradual relaxation of the unofficial moratorium on transgenic crops
in Europe is a good indication that the public and regulatory perception toward
transgenic crops is improving, and this trend is expected to drive the
market," notes the analyst.
Frost & Sullivan Growth Partnership Service
Based on extensive and in-depth research, real-world consulting work, and new
theories tested in hundreds of companies across many industries, Frost &
Sullivan has evolved its Growth Partnership Services (GPS) program that provides
established and emerging firms with powerful growth visions. Moving beyond token
mission statements, GPS provides an actionable vision to growth consulting
partners by illustrating how key intelligence and strategic research based on
defined goals can guide day-to-day behavior and overall company direction. The
foundation of Frost & Sullivans GPS includes:
- Assisting companies to reach their full potential in the core business
- Providing growth strategies to help companies expand into related
businesses
- Preemptively redefining the core business during market turbulence
- Applying the Frost & Sullivan framework to identify and address common
mistakes resulting from misaligned corporate strategies
- Recommending growth management strategies through continuous partnership
To maximize the potential for growth within a firms internal and external
environment, Frost & Sullivan consultants can facilitate the creation of
strategic programs that deliver improved market success. Frost & Sullivans
strengths lie in combining strategic understanding with market expertise and
applying these with absolute commitment to its clients growth.
Table of Contents
1 STRATEGIC ANALYSIS OF THE WORLD PLANT MOLECULAR FARMING MARKET
Overview
Research Scope & Methodology
Introduction & Background
World Industry Dynamics
- Influences on the Plant Molecular Farming Market
- Global Distribution of Transgenic Crops
- Key Market Engineering Measurements - World Biopharmaceuticals Market
- Total Market Revenue Forecasts - World Biopharmaceuticals Market
World Market Dynamics
- Key Challenges for the World Plant Molecular Farming Market
- Key Market Trends
- Current World Market Status
- Market Drivers
- Market Restraints
- Geographical World Industry Distribution
- Research Trends - Products in Development
- Worldwide Industry Participants
North American Market Dynamics
- North American Market Dynamics
- Current Industry Status - North America
- Forecast Assumptions
- Key Market Engineering Measurements
- Total Market Revenue Forecasts
- Market Analysis
- Product Timeline - North American Competitors
- Competitive Profiles
European Market Dynamics
- European Market Dynamics
- Current Industry Status - Europe
- Key Market Engineering Measurements
- Total Market Revenue Forecasts
- Market Analysis
- Product Timeline - European Competitors
- Competitive Profiles
Rest of World Market Dynamics
- Rest of World Market Dynamics
- Key Participants: Rest of World
Strategic Analysis & Reccomendations
- Strategic Analysis & Recommendations
- Key Challenges and Strategic Proposals
- Strategic Anticipation
- Market Maturation Process
- Market Penetration Strategy
- Competitive Framework
- Potential Threats
- Meeting the Challenge
Frost & Sullivan Awards
- Frost & Sullivan Awards Description
- Growth Strategy Leadership Award
- Technology Leadership Award
- Entrepreneurial Company Award
- Market Leadership Award
- Product Differentiation Innovation Award
Decision Support Databases
- Number of Biotechnology Companies - Western Europe and North America
(1999-2006)
- Number of Biotechnology European Patents Filed (1996 - 2000)
- Governmental R&D Investment in Biotechnology (1996-2000)
- Pharmaceutical R&D Expenditure 1999 - 2006
Frost & Sullivan
- Healthcare Team
- Our Capabilities
